Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743544 | 0.95 | MAP3K14 (0.46) | MAP3K14SRCKCNH2PRKDCMAP4K4 | |
| SCHEMBL12743907 | 0.95 | MAP3K14 (0.46) | MAP3K14SRCKCNH2PRKDCMAP4K4 | |
| SCHEMBL12743240 | 0.88 | MAP3K14 (0.52) | MAP3K14SRCKCNH2TBK1PRKDC | |
| SCHEMBL12743918 | 0.87 | MAP3K14 (0.43) | MAP3K14MAP4K4LRRK2CNR2ALK | |
| SCHEMBL12743891 | 0.87 | MAP3K14 (0.43) | MAP3K14MAP4K4LRRK2CNR2ALK | |
| SCHEMBL1612839 | 0.86 | MAP3K14 (0.69) | MAP3K14MAP4K4LRRK2 | |
| SCHEMBL12743532 | 0.83 | SRC (0.37) | MAP3K14SRCTBK1LRRK2ALK | |
| SCHEMBL12743757 | 0.82 | MAP3K14 (0.39) | MAP3K14KCNH2TBK1PRKDCMAP4K4 | |
| SCHEMBL1614897 | 0.82 | MAP3K14 (0.64) | MAP3K14MAP4K4LRRK2 | |
| SCHEMBL1614900 | 0.82 | MAP3K14 (0.64) | MAP3K14MAP4K4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | MAP3K14 17/4885SRC 230/4885KCNH2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.